Membrane Functionalized Nanoparticles for Ligand Screening

用于配体筛选的膜功能化纳米颗粒

• 批准号: 10325234
• 负责人: Colleen Janczak
• 金额: $ 24.12万
• 依托单位: SCINTILLATION NANOTECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2022-10-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10325234
• 关键词: Adsorption; Agonist; Antibodies; Area; Beta Particle; Binding; Binding Proteins; Biological; Biological Assay; Biomedical Research; Biotin; Caliber; Carbohydrates; Categories; Chelating Agents; Chemicals; Chemistry; Deposition; Detection; Development; Disease; Elements; Environment; Enzyme Inhibitor Drugs; Evaluation; Feedback; G-Protein-Coupled Receptors; G-substrate; Government; Histidine; Hybrids; Industrialization; Innovation Corps; Interview; Ions; Knowledge; Label; Laboratory Research; Legal patent; Letters; Ligands; Liquid substance; Mass Spectrum Analysis; Measures; Membrane; Membrane Lipids; Membrane Proteins; Methods; Microscopy; Modification; Molecular; Nanotechnology; Nickel; Nicotinic Receptors; Optics; Outcome; Penetration; Phase; Phospholipids; Play; Polymers; Potassium Channel; Preparation; Property; Proteins; Radiation; Radioisotopes; Radiometry; Reproducibility; Research; Research Personnel; Research Project Grants; Role; Sampling; Scintillation Counting; Series; Signal Transduction; Silicon Dioxide; Small Business Innovation Research Grant; Sodium Chloride; Solubility; Structure; Surface; Techniques; Technology; Thinness; Time; absorption; aqueous; base; biomaterial compatibility; detection assay; detection sensitivity; drug discovery; fluorophore; imaging modality; innovation; interest; nanomaterials; nanoparticle; novel; particle; prevent; programs; protein function; public health relevance; receptor; receptor binding; research clinical testing; response; screening; sensor; small molecule; tool

Radioisotope (RI) labels remain a critical tool for drug discovery applications, particularly for measuring analytes that are not detectable by traditional optical microscopy or electrochemical methods. Drug discovery applications require minimal perturbation of the compounds of interest, preventing the use of large labels that significantly change the structure and properties of the compounds, particularly for small molecules. RI labels play a fundamental role in the high-sensitivity detection of compounds as diverse as small molecule enzyme inhibitors, receptor agonists and antagonists, carbohydrates and carbohydrate derivatives, proteins, and many others. RIs facilitate highly sensitive detection with minimal perturbation of the size and structure of the analyte, compared to fluorescent labels, a particularly important property in drug discovery applications. RI labels provide unparalleled sensitivity and precision for ligand-receptor binding assays, including G-protein coupled receptor assays. Unfortunately, the low energy and short penetration depth of most common, biologically relevant RIs also complicate detection, limiting the capabilities for this approach. Scintillation Nanotechnologies, INC was founded in 2018 around a series of patent-pending, radioisotope- responsive, hybrid nanomaterials. that overcome several key limitations associated with traditional radioisotope counting methods. Scintillation Nanotechnologies has developed a novel nanomaterial, termed nanoSPA, for sensitive detection of low-energy radioisotopes in intracellular environments. nanoSPA presents a number of advantages compared to other methods for imaging small molecules, including a) enhanced compatibility with aqueous samples; b) a high-surface area to volume (SA/V) ratio to enhance β-particle detection; c) an easily modified surface for attachment of biomolecules and other chemical species; d) more reproducible surface chemistry. In this SBIR application, we propose to further develop nanoSPA with an emphasis on enhanced surface functionalization using a diverse range of critically needed surface functionalities and to characterize the resulting nanoSPA materials with respect to key quantitative criteria necessary to demonstrate the key commercial potential of this platform. Once successfully developed, nanoSPA will provide an important new tool for biomedical research.

放射性同位素(RI)标记仍然是药物发现应用的关键工具，特别是在测量 传统光学显微镜或电化学方法无法检测到的分析物。药物发现 应用需要对感兴趣的化合物进行最小程度的扰动，防止使用大标签 显著改变化合物的结构和性质，特别是对小分子。国际扶轮标签 在从小分子酶到各种化合物的高灵敏度检测中发挥着基础性作用 抑制剂、受体激动剂和拮抗剂、碳水化合物和碳水化合物衍生物、蛋白质和许多 其他。RIS有助于以分析物的大小和结构的最小扰动进行高灵敏检测， 与荧光标记相比，荧光标记在药物发现应用中具有特别重要的特性。国际扶轮标签提供 包括G蛋白偶联受体在内的配体-受体结合分析的无与伦比的灵敏度和精确度 化验。不幸的是，最常见的、与生物相关的RIS能量低、穿透深度短 还会使检测复杂化，从而限制了此方法的功能。 闪烁纳米技术公司成立于2018年，围绕着一系列正在申请专利的放射性同位素- 响应性强的混合纳米材料。它克服了与传统放射性同位素相关的几个关键限制 计数方法。闪烁纳米技术已经开发出一种新的纳米材料，称为纳米SPA，用于 细胞内环境中低能放射性同位素的灵敏检测。NanSPA提供了许多 与其他小分子成像方法相比的优点，包括a)增强了与 水样；b)高比表面积/体积(SA/V)，以增强β颗粒检测；c)轻松 用于附着生物分子和其他化学物种的改性表面；d)更具重复性的表面 化学反应。 在这种SBIR应用中，我们建议进一步开发纳米SPA，重点是增强表面 使用各种急需的表面功能进行功能化，并表征所产生的 有关纳米SPA材料的关键定量标准，以展示关键的商业 这个平台的潜力。一旦成功开发，NanSPA将提供一个重要的新工具 生物医学研究。